entecavir and HCC risk

[stef2011]

J Viral Hepat. 2015 Feb;22(2):118-25. doi: 10.1111/jvh.12283. Epub 2014 Jul 15.
Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV1, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group.
Author information
Abstract
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg-negative CHB patients treated with entecavir. HBeAg-negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0-4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial agent. In conclusion, our large nationwide study indicates that the HCC risk remains increased in entecavir-treated HBeAg-negative CHB patients with cirrhosis, particularly of older age, at least for the first 5 years. The HCC risk does not seem to be significantly reduced with entecavir compared with antiviral therapy starting with lamivudine.
© 2014 John Wiley & Sons Ltd.
KEYWORDS:
cirrhosis; entecavir; hepatitis B; hepatocellular carcinoma; lamivudine

[terrywillbeok]

I agree with you. steff helped me a lot. he is a very good man , he tries to help a lot of ppl in this forum . I also think flyinsky you are a kind person too.=D

[mer971]

I think you are wrong. Nobody says that he is a doctor, but his knowledge about hepB is more accurate than many many stupid general and family doc. Even, some of them says,oh is nothing, go relax.You don't need a diploma to work whatever. If you know something everybody would appreciate it. I appreciate Steff too much , he is willing to answer and give us things that I didn't know. I learned more about this disease here and from him. Hep B is not a flu, a sore, its a bad virus that we are suffering, and soon its days are coming to the end,as it comes for hep C. What do we have to keep away this virus? Who needs treatment the best cure is tenofovir, and pegint, sequential therapy, not monotherapy.

[flyinsky]

Yes true you are right just I don't like a domination of one opinion even false.

[Ibro982003]

Hey come on stif2011 & flyinsky, we are here in this form for a helpful discussion plz let's unite and eradicate this dirty disease from this earth. Thank you to bith

[flyinsky]

And any one contradict you........is not good person

[flyinsky]

Remember always you are patient not doc